Celgene set to obtain Impact Biomedicines to develop Fedratinib
Celgene Corporation and Impact Biomedicinessigned and agreement that entails acquisition of Impact Biomedicines enabling development of fedratinib for myelofibrosis and polycythemia…
Read More...
Read More...
